Takeda Korea has achieved continuous success in expanding reimbursement for its anticancer drugs, increasing the company’s hold over the market.

According to industry sources, starting from April 1st, the government has decided to grant reimbursement for Takeda Korea’s antibody-drug conjugate ‘Adcetris (brentuximab vedotin)’ as a first-line treatment for Hodgkin and non-Hodgkin lymphoma and its anaplastic lymphoma kinase(ALK) tyrosine kinase inhibitor (TKI) ‘Alunbrig (brigatinib)’ as a first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC).

Takeda Korea had also previously received approval to expand the scope of reimbursement for its poly ADP-ribose poly